股票代码：688301 股票简称：奕瑞科技 债券代码：118025 债券简称：奕瑞转债 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为中金公司所作的承诺 或声明。在任何情况下，投资者依据本报告所进行的任何作为或不作为，中金公 司不承担任何责任。 1 中国国际金融股份有限公司作为奕瑞电子科技集团股份有限公司（以下简称 "奕瑞科技"、"发行人"、或"公司"）向不特定对象发行可转换公司债券（债券 简称："奕瑞转债"，债券代码：118025，以下简称"本次债券"）的保荐机构、 主承销商和受托管理人，持续密切关注对债券持有人权益有重大影响的事项。根 据《公司债券发行与交易管理办法》《公司债券受托管理人执业行为准则》《可转 换公司债券管理办法》等相关规定、本次债券《受托管理协议》的约定以及发行 人于 2025 年 4 月 26 日披露的《奕瑞电子科技集团股份有限公司关于变更注册地 资本、经营范围并修订公司章程的公告》及《奕瑞电子科技集团股份有限公司 2024 年年度报告》，现就本次债券重大事项报告如下： 奕瑞电子科技集团股份有限公司 向不特定对象发 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1][6][7]. Core Insights - The company's main business is stabilizing, with new technologies flourishing, as evidenced by the launch of various innovative products in the medical and industrial sectors [3][4]. - The company reported a revenue of 1.831 billion yuan in 2024, a slight decrease of 1.74% year-on-year, with a net profit of 465 million yuan, down 23.43% year-on-year [3]. - The company is actively expanding its product matrix and has made significant advancements in the development of new core components and X-ray comprehensive solutions [4][6]. Financial Performance Summary - In 2024, the company achieved a revenue of 1.831 billion yuan, with a gross margin of 50.11% and a net margin of 24.59% [3]. - For Q1 2025, the company reported a revenue of 482 million yuan, a year-on-year decrease of 1.92%, but a net profit increase of 2.74% to 143 million yuan [3]. - The company forecasts revenues of 2.162 billion yuan in 2025, with a projected net profit of 574 million yuan, reflecting a growth rate of 18% and 23% respectively [5][6]. Product Development and Market Position - The company has successfully launched several new products, including high-resolution detectors and various X-ray sources, enhancing its competitive edge in the market [3][4]. - The company is focusing on R&D investments in CMOS detectors, CT detectors, and photon counting detectors, which are expected to drive future growth [3][4]. - The company aims to strengthen its position as a core supplier of digital X-ray components and comprehensive solutions through continuous innovation and global business expansion [6].

Core Viewpoint - The financial performance of Yirui Technology in 2024 shows a decline in revenue and net profit, indicating potential challenges in the market despite growth in cash flow from operating activities and increased investment in R&D [1][2][3]. Financial Performance - The company reported a revenue of 1.83 billion, a decrease of 1.74% compared to 2023 [2]. - The net profit attributable to shareholders was 465 million, down 23.43% year-on-year [1][2]. - The gross profit margin was 50.15%, reflecting a decline of 6.83 percentage points from the previous year [2]. Expense Changes - Sales expenses decreased by 13.10% to 69.68 million [3]. - Management expenses increased by 36.02% to 138 million [3]. - R&D expenses reached 310 million, an increase of 18.08%, representing 16.94% of total revenue [3][6]. Cash Flow - The net cash flow from operating activities was 360 million, up 5.91% year-on-year [3]. - The net cash flow from investing activities was -1.13 billion, primarily for ongoing construction projects [3]. - The net cash flow from financing activities increased by 219.67% to 1.15 billion, mainly for project loan financing [3]. Company Overview - Yirui Technology, established on March 7, 2011, specializes in the R&D, production, sales, and service of digital X-ray detectors and related core components [5]. - The company is headquartered in Shanghai, with production bases in Jiangsu, Zhejiang, Anhui, South Korea, and the United States [5]. R&D Investment - R&D investment in 2024 reached 310 million, marking an 18.08% increase [6]. - The company completed 78 IP applications in new core components and scientific instruments, with 37 granted [6]. Sales and Market Position - In 2024, the sales volume of digital X-ray detectors reached 119,200 units, showing a steady growth trend [7]. - Revenue from solutions and technical services amounted to 96.46 million, a significant increase of 262.56% [7].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance in the next 6-12 months [1][5]. Core Views - The company reported a revenue of 1.831 billion RMB in 2024, a decrease of 1.74% year-on-year, and a net profit of 465 million RMB, down 23.43% year-on-year. In Q1 2025, revenue was 482 million RMB, a decrease of 1.92%, while net profit increased by 2.74% to 143 million RMB [3][8]. - The company plans to distribute a cash dividend of 10.00 RMB for every 10 shares to all shareholders, reflecting its commitment to returning value to investors [3]. - Despite short-term performance pressures due to industry challenges, the company is viewed as a leader in the detector market, with a strong long-term growth potential [3][5]. Summary by Sections Financial Performance - The company’s revenue and net profit for 2024 were 1.831 billion RMB and 465 million RMB, respectively. The projected net profits for 2025-2027 are 680 million RMB, 743 million RMB, and 836 million RMB, with corresponding EPS of 4.75, 5.19, and 5.84 RMB [7][9]. - The company’s EBITDA for 2024 is projected at 472 million RMB, with a significant increase expected in subsequent years [7]. Market Position and Strategy - The company is focusing on increasing R&D investments, with 310 million RMB allocated in 2024, aimed at developing new products such as digital X-ray detectors and various types of industrial detectors [8]. - The company has completed its layout for comprehensive solutions, including key components like high-voltage generators and X-ray sources, with several products entering mass production in 2024 [8]. Valuation Metrics - The company’s projected P/E ratios for 2025, 2026, and 2027 are 25.8, 23.6, and 21.0, respectively, indicating a potential for valuation improvement as earnings grow [5][7]. - The projected dividend per share for 2025 is 1.5 RMB, with a dividend yield of 1.2% [7].

Core Insights - The company experienced a decline in its main detector business due to weak industry demand, but new products showed significant growth [1] - The overall gross margin decreased, coupled with increased management and financial expenses, leading to a drop in net profit margin [2] - The company is optimistic about a turnaround in performance for the full year 2025, supported by improved market conditions and contract liabilities growth [3] - The company is pursuing vertical integration and horizontal expansion to establish itself as a comprehensive component supplier [4] - The company plans to raise funds through a private placement to support the construction of X-ray vacuum devices and comprehensive solutions, which will enhance production capacity [5] Financial Performance - In 2024, the company achieved total revenue of 1.831 billion yuan, a year-on-year decrease of 1.74%, with the detector business revenue at 1.490 billion yuan, down 11.99% [1] - The overall gross margin for 2024 was approximately 50.11%, a decline of 7.73 percentage points year-on-year, with the detector gross margin at 56.65%, down 3.48 percentage points [2] - The net profit for 2024 was 465 million yuan, a year-on-year decline of 23.43%, resulting in a net profit margin of 25.40%, down 7.19 percentage points [2] Business Development - The company is actively developing upstream components and materials for detectors, with successful R&D and production of 2D collimators for medical CT and security CT applications [4] - The company has completed the R&D and initial production of high-voltage generators and combination ray sources, with plans for further expansion into more application areas [4] - The company aims to increase production capacity by 77,000 tubes and 19,300 sets of X-ray comprehensive solutions through a planned investment project [5] Future Outlook - The company expects revenue growth to reach 2.208 billion yuan in 2025, with net profit projected at 648 million yuan, indicating a potential performance reversal [5] - The company maintains a positive long-term growth outlook, supported by ongoing market recovery and expansion initiatives [5]

Event Overview - The company reported its Q1 2024 and Q1 2025 financial results, with 2024 revenue at 1.831 billion yuan, down 1.74% year-on-year, and net profit attributable to shareholders at 465 million yuan, down 23.43% year-on-year [1] - For Q1 2025, revenue was 482 million yuan, down 1.92% year-on-year but up 1.32% quarter-on-quarter, with net profit attributable to shareholders at 143 million yuan, up 2.74% year-on-year and up 90.72% quarter-on-quarter [1] Performance Meets Market Expectations - In 2024, the detector business generated revenue of 1.49 billion yuan, down 11.99% year-on-year, while solution/technical service revenue surged to 96 million yuan, up 262.56% year-on-year, and core component sales reached 126 million yuan, up 45.49% year-on-year [2] Margin Pressure and Increased R&D Investment - The company's gross margin for 2024 was 50.11%, down 7.73% year-on-year, while Q1 2025 gross margin was 48.92%, down 4.41 percentage points year-on-year but up 10.71 percentage points quarter-on-quarter [3] - The company increased its R&D expenses to 310 million yuan in 2024, up 18.08% year-on-year, reflecting a commitment to developing new technologies related to core components and solutions [3] Development of Digital X-ray Core Components and Comprehensive Solutions - In 2024, the company launched several new medical and industrial products, with high-end DSA detectors entering mass production and significant progress in photon counting detector technology [4] - The company began mass production of economical and mid-to-high-end CT high-voltage generators, achieving international leadership in the medical CT high-voltage generator sector [4] - The company successfully developed various types of X-ray tubes for industrial and medical applications, with some products nearing mass production [5] Investment Recommendations - Based on the 2024 and Q1 2025 reports, revenue forecasts for 2025 and 2026 have been adjusted to 2.405 billion yuan and 3.057 billion yuan, respectively, with a new revenue forecast for 2027 at 3.847 billion yuan, reflecting year-on-year growth of 31.3%, 27.1%, and 25.8% [7] - Expected net profits for 2025 and 2026 are projected at 702 million yuan and 920 million yuan, respectively, with a new forecast for 2027 at 1.202 billion yuan, indicating year-on-year growth of 51.0%, 31.0%, and 30.7% [7] - The company maintains a "buy" rating with a stock price of 119.06 yuan as of April 25, 2025, corresponding to PE ratios of 24.25x, 18.51x, and 14.17x for 2025, 2026, and 2027, respectively [7]

Summary of Yirui Technology Conference Call Company Overview - **Company**: Yirui Technology - **Year**: 2024 - **Industry**: Medical Imaging and Industrial Detection Key Points Financial Performance - **2024 Revenue**: 18.3 billion, a slight decrease of 1.7% year-on-year [2][3] - **Net Profit**: 4.65 billion, down 23.4% year-on-year; Non-recurring net profit: 4.39 billion, down 25.8% year-on-year [3] - **Core Business Growth**: Core components revenue increased by approximately 50% to 1.26 billion; Solutions and technical services revenue surged by about 260% to 960 million [2][3] - **Gross Margin**: 50%, down six percentage points year-on-year due to changes in sales structure, slight price reductions in detectors, production cost fluctuations, and accounting adjustments [2][3] Market Dynamics - **Weak Demand**: Domestic medical, dental, and industrial end markets showed weak demand, leading to a 12% decline in detector business [2][3] - **R&D Investment**: R&D expenses reached 310 million, an increase of 50 million year-on-year, with significant progress in product expansion [2][3] - **2025 Q1 Performance**: Revenue remained stable at 4.8 billion; net profit increased by 2.7% to 1.43 billion; non-recurring net profit decreased by 9.2% [5] Strategic Initiatives - **Response to Tariffs**: Established factories in Korea and the U.S. to mitigate the impact of U.S. tariffs; shifting export orders to these locations [2][7][8] - **Domestic Market Opportunities**: The increase in domestic production due to tariffs is beneficial for the company in the high-end X-ray medical imaging sector [8][9] Product Development - **CT Tube Development**: Completed prototype development for CT tubes, currently in client testing phase; significant progress in CT detector core components [10][11] - **Vertical Integration**: Achieved batch delivery in core components like CT ceramics and PD collimators, enhancing competitiveness [4][14] Future Outlook - **2025 Revenue Growth Target**: Aiming for a 20% revenue growth despite uncertainties in domestic medical policies and market recovery [2][5] - **Market Share Goals**: Current global market share is approximately 20%, with a mid-term target of 50% and a long-term goal of over 70% [17] - **Focus on High-End Products**: Plans to increase market share in high-end products, particularly in the medical imaging sector [17] Challenges and Risks - **Trade Tensions**: U.S.-China trade tensions pose risks but also create opportunities for domestic market growth [8][9] - **Economic Factors**: Economic conditions and geopolitical factors have affected overseas revenue, with expectations for gradual recovery in new projects [16] Additional Insights - **Supply Chain Strategy**: Emphasizing vertical integration to enhance supply chain efficiency and product delivery [4][14] - **Collaboration with Major Clients**: Engaging with large clients to boost brand strength and market share, particularly in high-end medical equipment [17][22] Conclusion Yirui Technology is navigating a challenging market environment with strategic initiatives aimed at growth through innovation, market expansion, and operational efficiency. The company is well-positioned to leverage domestic opportunities while addressing the impacts of international trade dynamics.

奕瑞电子科技集团股份有限公司章程 奕瑞电子科技集团股份有限公司 章 程 2025 年 4 月 | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 宗旨和经营范围 | 2 | | 第三章 | 股份 | 2 | | 第一节 | 股份发行 | 2 | | 第二节 | 股份增减和回购 | 4 | | 第三节 | 股份转让 | 5 | | 第四章 | 股东和股东大会 | 6 | | 第一节 | 股东 | 6 | | 第二节 | 股东大会的一般规定 8 | | | 第三节 | 股东大会的召集 13 | | | 第四节 | 股东大会提案与通知 14 | | | 第五节 | 股东大会的召开 16 | | | 第六节 | 股东大会的表决和决议 18 | | | 第五章 | 董事会 | 23 | | 第一节 | 董事 | 23 | | 第二节 | 董事会 | 27 | | 第三节 | 董事会专门委员会 32 | | | 第六章 | 总经理及其他高级管理人员 33 | | | 第七章 | 监事会 | 35 | | 第一节 | 监事 | 35 | | 第二节 | 监事会 | 36 | | 第八章 ...

奕瑞电子科技集团股份有限公司 2024 年度独立董事述职报告 作为奕瑞电子科技集团股份有限公司（以下简称"公司"）的独立董事，在 2024 年度，本人严格按照《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司治理准则》《上市公司独立董事管理办法》《关于加强社会公众股股东 权益保护的若干规定》以及《奕瑞电子科技集团股份有限公司章程》（以下简称 "《公司章程》"）和《奕瑞电子科技集团股份有限公司独立董事工作制度》等相 关规定，认真履行工作职责，积极参与公司股东大会、董事会及各专门委员会， 勤勉履职，认真审议各项议案，发挥专业特长，为公司经营发展提出合理化建议。 从公司整体利益出发，充分发挥独立董事的应有作用，努力维护公司和全体股东 特别是中小股东的合法权益。现将 2024 年度履行独立董事职责工作情况汇报如 下： 一、独立董事的基本情况 （一）独立董事人员情况 报告期内，公司第三届董事会成员为 8 名，其中独立董事 3 名，分别为高永 岗先生、Xiangli Chen（陈向力）先生、储小青先生。独立董事占董事会人数达 到三分之一，符合相关法律法规及公司制度的规定。 （二）独立董事任职董事会专门委员会的情 ...

2024 年度独立董事述职报告 奕瑞电子科技集团股份有限公司 作为奕瑞电子科技集团股份有限公司（以下简称"公司"）的独立董事，在 2024 年度，本人严格按照《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司治理准则》《上市公司独立董事管理办法》《关于加强社会公众股股东 权益保护的若干规定》以及《奕瑞电子科技集团股份有限公司章程》（以下简称 "《公司章程》"）和《奕瑞电子科技集团股份有限公司独立董事工作制度》等相 关规定，认真履行工作职责，积极参与公司股东大会、董事会及各专门委员会， 勤勉履职，认真审议各项议案，发挥专业特长，为公司经营发展提出合理化建议。 从公司整体利益出发，充分发挥独立董事的应有作用，努力维护公司和全体股东 特别是中小股东的合法权益。现将 2024 年度履行独立董事职责工作情况汇报如 下： 一、独立董事的基本情况 （一）独立董事人员情况 报告期内，公司第三届董事会成员为 8 名，其中独立董事 3 名，分别为高永 岗先生、Xiangli Chen（陈向力）先生、储小青先生。独立董事占董事会人数达 到三分之一，符合相关法律法规及公司制度的规定。 （二）独立董事任职董事会专门委员会的情 ...